Evoqua Water Technologies to acquire renal business from STERIS

The acquisition will strengthen Evoqua’s offerings in medical water purification systems and aftermarket services.

Evoqua Water Technologies has entered into an agreement to acquire the assets of the renal business operated by Mar Cor Purification and Cantel Medical, subsidiaries of STERIS, for US$196.3 million. The latter is a manufacturer and servicer of medical water, commercial and industrial solutions in North America, and will expand Evoqua’s service footprint and further its reach into the healthcare vertical market.

The acquired business is headquartered in Plymouth, Minnesota, with 27 service and regeneration facilities in the US and Canada, and offers technical expertise in designing, building, and servicing high-purity water treatment systems to an installed base of approximately 5,500 sites. The acquired business’ installed base and large footprint is expected to provide Evoqua with a recurring stream of service and aftermarket revenues in the market.

The transaction is expected to close during Q2 2022. Upon closing the transaction, the business will be part of Evoqua’s Integrated Solutions and Services segment.

Ron Keating, CEO of Evoqua, concluded: “Mar Cor’s expertise and extensive network are a natural fit with Evoqua’s customer-centric water treatment solutions and service. This addition will further strengthen our service footprint in North America while expanding our offerings in the healthcare market.”